LFMD
LifeMD, Inc.
$4.70
-4.08%
$227.3M
No data for this timeframe.
Vol
Market Cap$227.3M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders48 funds
Inst. Value$43.9M
Inst. Activity8 buys / 3 sells
Reddit Sentiment58° Warm
SEC Reports1
Press Releases3
Exchange Nasdaq·Sector Services-Offices & Clinics of Doctors of Medicine·Inc. DE·CIK 0000948320·Prev Close $4.90
Recent Activity
Jun 5, 2026
short_volume
Short Volume: LFMD — 66.2% short (0.4M / 0.6M)
Short: 388,383 | Exempt: 400 | TRF Vol: 586,713 | Short Ratio: 66.2% | Off-exchange volume (dark poo
Jun 1, 2026
Insider
Sripad Umesh was granted 75,000 shares
Chief Technology Officer
May 11, 2026
Insider
Kavthekar Atul was granted 337,500 shares
Chief Financial Officer
Apr 27, 2026
SEC
LifeMD announced it will report Q1 2026 earnings on May 6, 2026, after market close, followed by a conference call. No f
PRESS-RELEASE — Impact 3/10
Mar 31, 2026
Press
LifeMD launched a subscription program for Novo Nordisk's Wegovy® (semaglutide), offering patients up to $1,200 in annua
Impact 4/10
Mar 30, 2026
Insider
Pisano Christopher A was granted 200,000 shares
Chief Marketing Officer
Inst.
ROYCE & ASSOCIATES LP — ADD
1,201,651 shares ($4.3M)
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
1,118,325 shares ($4.0M)
Price Targets
$9.88
+110.1% upside
Strong Buy
Current $4.70
Low $8.00
Median $10.00
High $15.00
8 analysts
$8.00
$15.00
Analyst Ratings
3Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 26, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 4, 2026 | BTIG | REITERATE | Buy → Buy |
| Mar 16, 2026 | Mizuho | UPGRADE | Neutral → Outperform |
| Mar 12, 2026 | Freedom Broker | MAINTAIN | Buy → Buy |
| Mar 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.04 ▼ -400.0% | $-0.09 — $0.00 | -302% YoY | 2 |
| Next Q | $0.17 ▲ +126.7% | $0.11 — $0.23 | 304% YoY | 2 |
| Current FY | $0.14 ▼ -3.6% | $0.02 — $0.25 | -8% YoY | 2 |
| Next FY | $0.52 ▲ +15.7% | $0.48 — $0.55 | 281% YoY | 2 |
Latest Reports
NEUTRAL
PRESS-RELEASE
3/10
LifeMD announced it will report Q1 2026 earnings on May 6, 2026, after market close, followed by a conference call. No f
Apr 27, 2026
NEUTRAL
Press
4/10
LifeMD launched a subscription program for Novo Nordisk's Wegovy® (semaglutide), offering patients up to $1,200 in annua
Mar 31, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $10.1M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $6.0M | — |
| ROYCE & ASSOCIATES LP | $4.3M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $4.0M | TRIM |
| STATE STREET CORP | $3.9M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Sripad Umesh | A | $0.00 |
| May 11, 2026 | Kavthekar Atul | A | $0.00 |
| Mar 30, 2026 | Pisano Christopher | A | $0.00 |
Reddit Sentiment
58°
Warm
Bearish
Neutral
Bullish
48 institutional holders with $43.9M total value (12,202,767 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, ROYCE. Net buying activity: 8 institutions added/increased vs 3 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 2,809,025 | $10.1M | 23.1% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1,663,696 | $6.0M | 13.7% | — |
| 3 | ROYCE & ASSOCIATES LP | 1,201,651 | $4.3M | 9.9% | ADD +32.1% |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 1,118,325 | $4.0M | 9.2% | TRIM -25.4% |
| 5 | STATE STREET CORP | 1,075,408 | $3.9M | 8.8% | ADD +57.0% |
| 6 | FEDERATED HERMES, INC. | 1,019,077 | $3.7M | 8.4% | DOUBLED +278.1% |
| 7 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 465,193 | $1.7M | 3.8% | — |
| 8 | GOLDMAN SACHS GROUP INC | 459,803 | $1.7M | 3.8% | — |
| 9 | MORGAN STANLEY | 364,489 | $1.3M | 3.0% | TRIM -66.6% |
| 10 | VANGUARD FIDUCIARY TRUST CO | 288,912 | $1.0M | 2.4% | — |
| 11 | MARSHALL WACE, LLP | 257,135 | $928.3K | 2.1% | — |
| 12 | VANGUARD PORTFOLIO MANAGEMENT LLC | 232,591 | $839.7K | 1.9% | — |
| 13 | CITADEL ADVISORS LLC | 155,600 | $561.7K | 1.3% | — |
| 14 | Nuveen, LLC | 136,949 | $494.4K | 1.1% | ADD +37.9% |
| 15 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 104,509 | $377.3K | 0.9% | — |
| 16 | CITADEL ADVISORS LLC | 103,900 | $375.1K | 0.9% | — |
| 17 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 81,500 | $294.2K | 0.7% | — |
| 18 | FRANKLIN RESOURCES INC | 66,643 | $240.6K | 0.5% | TRIM -56.6% |
| 19 | STIFEL FINANCIAL CORP | 57,139 | $206.3K | 0.5% | — |
| 20 | BANK OF AMERICA CORP /DE/ | 48,703 | $175.8K | 0.4% | TRIM -58.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| ROYCE & ASSOCIATES LP | ADD | 909,651 | 1,201,651 | +32.1% | $4.3M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,498,325 | 1,118,325 | -25.4% | $4.0M | 2026-Q1 |
| Nuveen, LLC | ADD | 99,308 | 136,949 | +37.9% | $494.4K | 2026-Q1 |
| DEUTSCHE BANK AG\ | NEAR_EXIT | 321,854 | 32,877 | -89.8% | $118.7K | 2026-Q1 |
| GROUP ONE TRADING LLC | ADD | 18,111 | 28,541 | +57.6% | $103.0K | 2026-Q1 |
| CWM, LLC | DOUBLED | 1,061 | 10,559 | +895.2% | $38.1K | 2026-Q1 |
| FMR LLC | DOUBLED | 1,978 | 10,121 | +411.7% | $36.5K | 2026-Q1 |
| Russell Investments Group, Ltd. | ADD | 3,544 | 5,334 | +50.5% | $19.3K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | DOUBLED | 52 | 118 | +126.9% | $426.00 | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 19,282 | 28,579 | +48.2% | $104.00 | 2026-Q1 |
| HRT FINANCIAL LP | TRIM | 32,466 | 10,114 | -68.8% | $36.00 | 2026-Q1 |
| FEDERATED HERMES, INC. | DOUBLED | 259,267 | 980,285 | +278.1% | $3.3M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 975,757 | 326,205 | -66.6% | $1.1M | 2025-Q4 |
| D. E. Shaw & Co., Inc. | TRIM | 444,520 | 287,398 | -35.3% | $980.0K | 2025-Q4 |
| Nuveen, LLC | NEAR_EXIT | 1,323,399 | 99,308 | -92.5% | $338.6K | 2025-Q4 |
| Verition Fund Management LLC | ADD | 33,889 | 54,893 | +62.0% | $187.2K | 2025-Q4 |
| FRANKLIN RESOURCES INC | TRIM | 123,914 | 53,736 | -56.6% | $183.2K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 107,741 | 44,238 | -58.9% | $150.9K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 25,766 | 44,162 | +71.4% | $150.6K | 2025-Q4 |
| GROUP ONE TRADING LLC | ADD | 12,275 | 18,111 | +47.5% | $61.8K | 2025-Q4 |
| FMR LLC | NEAR_EXIT | 19,705 | 1,978 | -90.0% | $6.7K | 2025-Q4 |
| CWM, LLC | NEAR_EXIT | 6,886 | 1,061 | -84.6% | $4.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 1,086,200 | 1,633,825 | +50.4% | $11.1M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 1,593,282 | 975,757 | -38.8% | $6.6M | 2025-Q3 |
| D. E. Shaw & Co., Inc. | TRIM | 1,219,804 | 444,520 | -63.6% | $3.0M | 2025-Q3 |
3 unique insiders with 3 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Sripad Umesh | Chief Technology Officer | AWARD | 75,000 | — | — |
| May 11, 2026 | Kavthekar Atul | Chief Financial Officer | AWARD | 337,500 | — | — |
| Mar 30, 2026 | Pisano Christopher A | Chief Marketing Officer | AWARD | 200,000 | — | — |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 3.0/10.
NEUTRAL
4/10
LifeMD launched a subscription program for Novo Nordisk's Wegovy® (semaglutide), offering patients u
Mar 31, 2026
NEUTRAL
3/10
LifeMD announced a cash dividend of $0.5546875 per share for its Series A Preferred Stock. This is a
Mar 24, 2026
BULLISH
8/10
LifeMD reported strong full-year 2025 results with 25% revenue growth to $194.1 million and a 309% i
Mar 9, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 3 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$9.88 mean target
+110.1% upside
Strong Buy (3.00)
$8.00 Low
$15.00 High
| Metric | Value |
|---|---|
| Current Price | $4.70 |
| Target Low | $8.00 |
| Target Mean | $9.88 |
| Target Median | $10.00 |
| Target High | $15.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.04 | $-0.09 | $0.00 | -301.8% | -400.0% | 0↑ 1↓ | $0.0B | -21.0% | 2 |
| Next Q 2026-09-30 |
$0.17 | $0.11 | $0.23 | 304.1% | +126.7% | 0↑ 1↓ | $0.1B | -2.7% | 2 |
| Current FY 2026-12-31 |
$0.14 | $0.02 | $0.25 | -7.8% | -3.6% | 0↑ 1↓ | $0.2B | 14.4% | 2 |
| Next FY 2027-12-31 |
$0.52 | $0.48 | $0.55 | 281.5% | +15.7% | 0↑ 1↓ | $0.3B | 17.5% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.045 | |
| 7d ago | $-0.045 | |
| 30d ago | $0.015 | -0.060 |
| 60d ago | $0.015 | -0.060 |
| 90d ago | $0.120 | -0.165 |
4 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 26, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 4, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 16, 2026 | Mizuho | UPGRADE | Neutral | Outperform |
| Mar 12, 2026 | Freedom Broker | MAINTAIN | Buy | Buy |
| Mar 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 10, 2026 | BTIG | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| Jan 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
58°
Warm
Bearish
Neutral
Bullish
2 mentions
1 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 9, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
$LFMD a telehealth company with a great outlook
▲ 5
💬 5
⚡ 0.0
On the Rebound — $MIGI, $HIT, $LFMD Bouncing
▲ 1
💬 0
⚡ 0.0
Jun 5, 2026
short_volume
Short Volume: LFMD — 66.2% short (0.4M / 0.6M)
Short: 388,383 | Exempt: 400 | TRF Vol: 586,713 | Short Ratio: 66.2% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
other
LifeMD Appoints Umesh Sripad as Chief Technology Officer
Seasoned Technology Executive Brings More Than Two Decades of Large-Scale Digital Transformation Experience to Support LifeMD’s Next Phase of Growth <
May 15, 2026
other
LifeMD to Participate in Upcoming Investor Conferences
<p align="justify">NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=EG8bSW8HTyZm81S1YdUnuXNJA2HMrdmBY5
May 6, 2026
earnings
LifeMD Reports First Quarter 2026 Results
<p align="center"><strong><em>Conference</em></strong> <strong><em>call begins at 4:30 p.m. Eastern time today</em></strong></p>
May 6, 2026
short_volume
Short Volume: LFMD — 60.0% short (0.4M / 0.7M)
Short: 404,147 | Exempt: 604 | TRF Vol: 673,107 | Short Ratio: 60.0% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
LFMD Q1 2026 Earnings Scheduled — 2026-05-06
May 4, 2026
earnings_calendar
LFMD Q1 2026 Earnings Scheduled — 2026-05-04
Apr 27, 2026
earnings
LifeMD to Report First Quarter 2026 Financial Results on May 6
<p align="justify">NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=SQaj39YrNdAnRN4K7zAZiyWQvPqUlB1z
Apr 23, 2026
short_volume
Short Volume: LFMD — 59.7% short (0.4M / 0.6M)
Short: 372,337 | Exempt: 999 | TRF Vol: 623,636 | Short Ratio: 59.7% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
short_volume
Short Volume: LFMD — 64.2% short (1.3M / 2.0M)
Short: 1,285,935 | Exempt: 33,942 | TRF Vol: 2,004,547 | Short Ratio: 64.2% | Off-exchange volume (dark pool + OTC)
Apr 10, 2026
other
LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
LifeMD expands its weight management program with the addition of Foundayo, offering eligible patients an oral alternative to injectable GLP-1 therapi
Mar 31, 2026
contract
LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program
Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD’s collaboration with Novo Nordisk <pre>Delivering up to $
Mar 24, 2026
dividend
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
<p align="justify">NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=771OWPRk8iZpS03ty8fZPQH4cYrUR1G1
Mar 11, 2026
short_interest
FTD: LFMD — 149,364 shares ($0.6M) failed to deliver
Settlement: 20260311, Price: $3.91, FTD Value: $584,013.24, LIFEMD INC
Mar 9, 2026
earnings
LifeMD Reports Fourth Quarter and Full Year 2025 Results
<p align="center"><strong><em>Conference</em></strong> <strong><em>call begins at 4:30 p.m. Eastern time today</em></strong></p>